We have first found that a VRP vaccine targeting TRP-2 is surprisingly effective in controlling tumor growth as opposed to vaccines based on the same viral delivery vector targeting the other melanosomal antigens, gp100 and tyrosinase. This evidence concerns the gene PMEL and neoplasm.